



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁶ : C12N 15/16, C07K 16/26, C12N 15/85, 5/10, A61K 31/70, C12N 15/11 // C12Q 1/68, C12N 15/62</p>	A1	<p>(11) International Publication Number: WO 97/48805 (43) International Publication Date: 24 December 1997 (24.12.97)</p>
<p>(21) International Application Number: PCT/US97/10315 (22) International Filing Date: 13 June 1997 (13.06.97) (30) Priority Data: 08/664,856 17 June 1996 (17.06.96) US (71) Applicant: CHILDREN'S MEDICAL CENTER CORPORATION [US/US]; 300 Longwood Avenue, Boston, MA 02115 (US). (72) Inventors: ZETTER, Bruce, R.; 120 Eliot Avenue, West Newton, MA 02165 (US). BAO, Lere; 1878 Beacon Street #3, Brookline, MA 02146 (US). (74) Agents: RESNICK, David, S. et al.; Dike, Bronstein, Roberts & Cushman L.L.P., 130 Water Street, Boston, MA 02109 (US).</p>	<p>(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: HUMAN THYMOSIN β15 GENE, PROTEIN AND USES THEREOF</p>		
<p>(57) Abstract</p> <p>The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin β family. This novel protein, herein referred to as thymosin β15, has the ability to bind and sequester G-actin, like other members of the thymosin β family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is directed to an isolated cDNA encoding the human thymosin β15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

Human Thymosin β 15 Gene, Protein and Uses Thereof

The work described herein was supported, in part, by National Institutes of Health grant CA37393. The U.S. Government has certain rights to this invention.

5

Background of the Invention

The present invention provides novel genes, proteins, and uses thereof including, methods for diagnosing and treating cancer, particularly metastatic cancer.

10

Most eukaryotic cells (exceptions include red blood cells and adult muscles) contain high concentrations, i.e., up to $\sim 250 \mu\text{mol/l}$, of monomeric actin. How such actin remains unpolymerized in the cytoplasm has remained a problem in cell biology (Nachmiar, V., *Current Opinion in Cell Biology*, 1993, 5:56). Profilin, originally
15 thought to be the actin-sequestering protein, is not present in sufficient amounts to account for more than part of the monomeric actin levels observed. Recently, an actin-sequestering 5 kD peptide was discovered in high concentration in human platelets (Safer, et al., *Proc. Natl. Acad. Sci USA* 1990 87:2536-2540) and shown to be identical
20 to a previously known peptide (Safer, et al., *J. Biol. Chem.*, 1991, 268:4029-4032) originally thought to be the thymic hormone, thymosin β_4 ($T\beta_4$) (D. Safer, *J. Muscle Res. Cell Motil*, 1992, 13:269-271). A detailed kinetic study of the interaction of $T\beta_4$ and actin (Weber, et al., *Biochemistry* 1992, 31:6179-6185)), together with
25 other studies (Yu, et al., *J. Biol. Chem.*, 1993, 268:502-509 and Cassimelds, et al., *J. Cell Biol.*, 1992, 119:1261-1270) support the

- 2 -

hypothesis that $T\beta_4$ and $T\beta_{10}$ function primary as G-actin buffers. Unpublished data (E. Hannappel) extend the function to several other β thymosins. $T\beta_4$ has also been shown to inhibit nucleotide exchange by actin, whereas profilin increases the rate of exchange (Coldschmidt-Clermont, et al., *Mol. Cell Biol.*, 1992, 3:1015-1025).

All vertebrates studied contain one or often two β -thymosins. Thus, the members of the β -thymosin family are believed to be important in all species. Three new family members (Low, et al., *Arch. Biochem. Biophys.*, 1992, 293:32-39 and Schmid, B., Ph.D Thesis, University of Tübingen 1989) have been found in perch, trout and in sea urchin, the first non-vertebrate source. The sequences are well conserved suggesting that actin sequestration is probably a property of all β -thymosins. However, when $T\beta_4$ was discovered and its sequence first determined in 1981 (Low, et al., *Proc. Natl. Acad. Sci.*, USA 1981, 78:1162-1166), data were presented that suggested two extracellular functions (Low, et al. supra and Rebar, et al., *Science* 1981, 214:669-671). Two recent papers indicate a different and unexpected effect of a tetrapeptide which may be derived from the amino terminus of $T\beta_4$.

Several reports demonstrate regulation of $T\beta_4$ or $T\beta_{10}$ synthesis at the transcriptional or translational level. An interferon-inducible gene (Cassimelds, et al., *J. Cell. Biol.* 1992, 119:1261-1270 and Sanders, et al., *Proc. Natl. Acad. Sci.* USA 1992, 89:4678-4682) is identical to the cDNA of human $T\beta_4$, and there are several genes for $T\beta_4$ in humans. (Clauss, et al., *Genomics* 1991, 9:75-180 and Gomez-Marquez, et al., *J. Immunol.* 1989, 143:2740-2744)

- 3 -

It would be desirable to identify new members of the β -thymosin family, particularly in humans.

Bao and Zetter reported in an abstract presented at the American
5 Association for Cancer Research annual meeting (March 18-22, 1995)
the differential expression of a novel mRNA expressed in high-
metastatic rat tumor cell lines, but not in a low metastatic variant.
cDNA was isolated and was reported to encode a protein with 68%
identity to the rat thymosin β 4. However, the nucleotide sequence and
10 the deduced amino acid sequence were not reported.

Summary of the Invention

We have now discovered that humans have a gene that encodes
a novel protein of the thymosin β family. This novel protein, herein
15 referred to as thymosin β 15, has the ability to bind and sequester
G-actin, like other members of the thymosin β family, but unlike what is
known about other members it also directly regulates cell motility in
prostatic carcinoma cells. We have isolated a cDNA of the human
thymosin β 15 gene (SEQ ID NO: 1) and have deduced the amino acid
20 sequence (SEQ ID NO: 2). We have shown that enhanced transcripts
(mRNA) and expression of the thymosin β 15 gene in non-testicular cells
has a high correlation to disease state in a number of cancers, such as
prostate, lung, melanoma and breast cancer, particularly metastatic
cancers. Accordingly, discovering enhanced levels of transcript or gene
25 product in non-testicular tissues can be used in not only a diagnostic
manner, but a prognostic manner for particular cancers.

The present invention provides isolated nucleic acids
(polynucleotides) which encode thymosin β 15 having the deduced

- 4 -

amino acid sequence of SEQ ID. NO: 2 or a unique fragment thereof. The term "unique fragment" refers to a portion of the nucleotide sequence or polypeptide of the invention that will contain sequences (either nucleotides or amino acid residues) present in thymosin β 15 (SEQ ID NO: 2) but not in other member of the thymosin family. This can be determined when the hybridization profile of that fragment under stringent conditions is such that it does not hybridize to other members of the thymosin family. Such fragments can be ascertained from Figure 3. A preferred set of unique fragments are those that contain, or contain polynucleotides that encode, amino acid 7 to 12 of SEQ ID NO: 2, amino acid 21 to 24 of SEQ ID NO: 2 and amino acid 36 to 45 of SEQ ID NO: 2. Preferably, the unique nucleotide sequence fragment is 10 to 60 nucleotides in length, more preferably, 20 to 50 nucleotides, most preferably, 30 to 50 nucleotides. Preferably, the unique polypeptide sequence fragment is 4 to 20 amino acids in length, more preferably, 6 to 15 amino acids, most preferably, 6 to 10 amino acids.

The polynucleotides of the present invention may be in the form of RNA or in the form of DNA, which DNA includes cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand. The coding sequence which encodes the mature polypeptides may be identical to the coding sequence shown in SEQ ID NO: 1 or may be a different coding sequence which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encodes the same protein as the DNA of SEQ ID NO: 1.

- 5 -

The polynucleotide may have a coding sequence which is a naturally occurring allelic variant of the coding sequence shown in SEQ ID NO: 1. As known in the art, an allelic variant is an alternate form of a polynucleotide sequence which may have a substitution,
5 deletion or addition of one or more nucleotides, which does not substantially alter the function of the encoded protein.

The present invention also provides an isolated polynucleotide segment which hybridize under stringent conditions to a unique portion
10 of the hereinabove-described polynucleotides, particularly SEQ ID NO:1. The segment preferably comprises at least 10 nucleotides. As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences. These isolated segments may be used in
15 nucleic acid amplification techniques, e.g., PCR, to identify and/or isolate polynucleotides encoding thymosin β 15.

As used herein a polynucleotide "substantially identical" to SEQ ID NO:1 is one comprising at least 90% homology, preferably at least
20 95% homology, most preferably 99% homology to SEQ ID NO: 1. The reason for this is that such a sequence can encode thymosin β 15 in multiple mammalian species.

The present invention further provides an isolated and purified
25 human thymosin β 15 having the amino acid sequence of SEQ ID NO: 2, or a unique fragment thereof, as well as polypeptides comprising such unique fragments, including, for example, amino acid 7 to 12 of SEQ ID NO: 2, amino acid 21 to 24 of SEQ ID NO: 2 and amino acid 36 to 45 of SEQ ID NO: 2.

- 6 -

In accordance with yet another aspect of the present invention, there are provided isolated antibodies or antibody fragments which selectively binds human thymosin β 15. The antibody fragments
5 include, for example, Fab, Fab', F(ab')₂ or Fv fragments. The antibody may be a single chain antibody, a humanized antibody or a chimeric antibody.

10 The term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotides or polypeptides present in a living animal is not isolated, but the same polynucleotides or DNA or polypeptides, separated from some or all of
15 the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

20

The present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.

25

The present invention further provides a method of treating a neoplastic cell expressing human thymosin β 15 by administering to the cell an effective amount of a compound which suppresses the activity or production of the human thymosin β 15. Preferably, the compound

- 7 -

interferes with the expression of the human thymosin β 15 gene. Such compounds include, for example, antisense oligonucleotides, ribozymes, antibodies, including single chain antibodies and fragments thereof.

5

Description of the Drawings

Figures 1A and 1B show differential mRNA display and Northern analysis of Dunning R-3327 rat prostatic adenocarcinoma variants. Total RNA from AT2.1 (lane 1), AT3.1 (lane 2) and AT6.1 (lane 3) cells were reverse-transcribed and amplified by PCR with a primer set, T₁₁ AG and a 10 mer AGGGAACGAG (SEQ ID NO:3) in the presence of [α 35-S]dATP. The PCR fragments were displayed on a 6% polyacrylamide gel and autoradiographed. The differentially expressed band is indicated by arrowhead. B. Northern blot analysis of thymosin β 15 gene. Two μ g of poly (A) RNA was isolated from Dunning R-3327 variants AT2. 1 (lane 1), AT3.1 (lane 2), AT6.1 (lane 3), and Mat Lylu (lane 4), fractionated on a 1.1% formaldehyde-agarose gel, transferred to Hybond-N+ nylon membrane (Amersham) and hybridized with a random primed (Grillon C, et al., *FEBS* 1990, 274:30-34) ³²P-labeled T β 15 cDNA fragment. The same blot was hybridized with a rat β -actin probe to demonstrate that equivalent amounts of RNA were loaded in each lane.

Figure 2 is the nucleotide sequence (SEQ ID NO.: 1) of T β 15 cDNA and the predicted amino acid sequence (SEQ ID NO.: 2) (single-letter code). The sequence numbers of the nucleotides and amino acids are indicated on the right side of the sequences. The translation initiation codon ATG is underlined, and the termination codon TAA is marked with an asterisk. A putative actin binding region is underlined. These

25

- 8 -

sequence data are available from GenBank under accession number U25684.

5 Figure 3 shows the alignment of the deduced T β 15 protein sequence and some of the other β thymosin isoforms. Regions of amino acid identity are represented by white letters boxed in black. Unboxed black letters correspond to nonidentical regions. Dots correspond to gaps introduced in the sequence to optimize alignment.

10 Figure 4 shows expression of T β 15 in various rat tissues. The multiple-tissue blot was obtained from Clontech. The blot was hybridized with the T β 15 cDNA probe. Rat GAPDH is a loading control.

15 Figures 5A and 5B show in situ hybridization with antisense riboprobe for T β 15 on prostatic adenocarcinoma patients. Figure 5A shows differential expression in tumors. The small arrow shows positive staining. The large arrow shows negative staining. Figure 5B shows that in poorly differentiated and invasive prostate carcinoma, single cells invading stroma display intense staining (arrow).

20

 Figures 6A, 6B and 6C show the effect of T β 15 on actin polymerization.

25 Figure 6A. 3 μ M of pyrene-labeled G-actin was polymerized in the presence of various amounts of GST-T β 4 fusion peptide (∇), GST-T β 15 (\blacktriangle) or GST alone (\circ). The final extent of polymerization was determined from the final levels of pyrene-labeled actin (fluorescence). All solutions contained 5.5 mM Tris, pH7.6, 167 μ M CaCl₂, 0.5 mM

- 9 -

glutathione, 167 μ M DTT, and 420 μ M ATP. Polymerization was induced by addition of 2 mM $MgCl_2$ and 150 mM KCl. Error bars denote the range of duplicate measurements made from separate dilutions of the fusion proteins.

5

Figure 6B. 2 μ M of pyrene-labeled G-actin was polymerized in the presence of various amounts of monomeric T β 15 that had been cleaved from GST by thrombin. The relative rates of polymerization were derived from the maximal rate of fluorescence increase in the initial phase of polymerization.

10

Figure 6C. The final extent of actin assembly was determined by the same methods used for the thymosin GST fusion peptides. Experimental conditions are those described for Figure 6B.

15

Figures 7A, 7B and 7C show serum stimulated migration of control transfected and T β 15 transfected Dunning R-3327 variants and their growth rate. Figure 7A. Vector control transfected (\circ , ∇) and T β 15 antisense (\bullet , \blacktriangledown) transfected AT3.1 cell clones. Figure 7B. Vector control transfected (\circ , ∇) and T β 15 sense transfected (\bullet , \blacktriangledown) AT2.1 cell clones. Data are expressed as the mean \pm SE (n = 4). Figure 7C. Growth curves of control transfected and T β 15 (sense or antisense) transfected Dunning R-3327 clones. Cells from vector control transfected AT2.1 (\circ), T β 15 sense transfected AT2.1 (\bullet), vector control transfected AT3.1 (∇) and T β 15 antisense transfected AT3.1 (\blacktriangledown) were plated at initial 10^4 cells/well in RPMI 1640 with 10% FBS and 250 nM dexamethasone in 12-well plates. Cells were harvested and counted at indicated times. Points represent the mean \pm SE (n = 3).

20

25

- 10 -

Figures 8A and 8B show Western analysis of thymosin β -GST fusion protein. Figure 8A is a Coomassie staining of GST-T β fusion proteins. Figure 8B is a Western analysis of GST-T β fusion proteins with affinity purified anti-T β 15 C-terminal peptide antibody. Lane 1: GST-T β 4; Lane 2: GST-T β 15; Lane 3: GST only

Figure 9 shows a Northern analysis of thymosin β 15 in mouse lung tumor cells. LA-4: mouse lung adenoma cell line; M27 and H59: metastatic variants derived from mouse Lewis lung adenocarcinoma cell line. Northern blot analysis revealed that the probe detected the thymosin β 15 mRNA expression in M27 cells, less expression in H59 cells, but no expression in LA-4 cells.

Figure 10A, 10B, 10C and 10 show immunohistochemical staining of human prostatic carcinoma tissues with an affinity purified polyclonal antibody to thymosin β 15. **A.** Nonmalignant prostatic epithelia (large arrow) and high-grade prostatic intraepithelial neoplasia (PIN) (small arrow). **B.** Moderately differentiated prostatic carcinoma showing heterogeneous immunostaining (small arrow, positive; large arrow, negative). **C.** Poorly differentiated prostatic carcinoma. **D.** Single cells invading stroma showing intense staining.

Figure 11 is a 1.4% agarose gel electrophoresis of RT-PCR amplified β thymosins from the rat prostatic cell lines. Lane 1, weakly metastatic AT2.1; lane 2, 3 and 4, highly metastatic AT3.1, AT6.1 and Mat Lyly; lane 5 and 6, nonmetastatic NbE and MC2; lane 7, weakly metastatic Fb2. β -actin PCR was used as internal control of each sample.

Detailed Description of the Invention

A well characterized series of cell lines that show varying metastatic potential has been developed from the Dunning rat prostatic carcinoma (Isaacs, et al., *Prostate* 9, 261-281 and Bussebakkers, et al., *Cancer Res.* 52,2916-2922 (1992)). Coffey and colleagues previously showed a direct correlation between cell motility and metastatic potential in the Dunning cell lines (Mohler, et al., *Cancer Res.* 48, 4312-4317 (1988), Parin, et al., *Proc. Natl. Acad. Sci, USA* 86, 1254-1258 (1989) and Mohler, et al., *Cancer Metast. Rev* 12, 53-67 (1993)). We compared gene expression in poorly metastatic and highly metastatic cell lines derived from Dunning rat prostate carcinoma using differential mRNA display. The results of these studies revealed the expression of a novel member of the thymosin beta family of actin-binding molecules, thymosin β 15. Using this information, we isolated and sequenced a cDNA encoding human thymosin β 15.

Although members of the thymosin β family have been shown to bind and sequester G-actin, they have not previously been demonstrated to alter cell motility. Our studies, however, reveal that this new member, thymosin β 15, directly regulates cell motility in prostatic carcinoma cells. We have shown that expression of thymosin β 15 is upregulated in highly metastatic prostate cancer cell lines relative to poorly metastatic or nonmetastatic lines. In addition, thymosin β 15 was expressed in human prostate carcinoma specimens but not in normal human prostate. Although not wishing to be bound by theory, this indicates that β 15 plays a role in the process of metastatic transformation.

- 12 -

The present invention provides a polynucleotide sequence encoding all or part of thymosin β 15 having the deduced amino acid sequence of SEQ ID NO:2 or a unique fragment thereof. A nucleotide sequence encoding human thymosin β 15 is set forth as SEQ ID NO:1.

5

The sequences of the invention may also be engineered to provide restriction sites, if desired. This can be done so as not to interfere with the peptide sequence of the encoded thymosin β 15, or may interfere to any extent desired or necessary, provided that the final product has the properties desired.

10

Where it is desired to express thymosin β 15 or a unique fragment thereof, any suitable system can be used. The general nature of suitable vectors, expression vectors and constructions therefor will be apparent to those skilled in the art.

15

Suitable expression vectors may be based on phages or plasmids, both of which are generally host-specific, although these can often be engineered for other hosts. Other suitable vectors include cosmids and retroviruses, and any other vehicles, which may or may not be specific for a given system. Control sequences, such as recognition, promoter, operator, inducer, terminator and other sequences essential and/or useful in the regulation of expression, will be readily apparent to those skilled in the art, and may be associated with the natural thymosin β 15 or with the vector used, or may be derived from any other source as suitable. The vectors may be modified or engineered in any suitable manner.

20

25

Correct preparation of nucleotide sequences may be confirmed,

- 13 -

for example, by the method of Sanger et al. (*Proc. Natl. Acad. Sci. USA* 74:5463-7 (1977)).

A cDNA fragment encoding the thymosin β 15 of the invention
5 may readily be inserted into a suitable vector. Ideally, the receiving
vector has suitable restriction sites for ease of insertion, but blunt-end
ligation, for example, may also be used, although this may lead to
uncertainty over reading frame and direction of insertion. In such an
instance, it is a matter of course to test transformants for expression, 1
10 in 6 of which should have the correct reading frame. Suitable vectors
may be selected as a matter of course by those skilled in the art
according to the expression system desired.

By transforming a suitable organism or, preferably, eukaryotic
15 cell line, such as HeLa, with the plasmid obtained, selecting the
transformant with ampicillin or by other suitable means if required, and
adding tryptophan or other suitable promoter-inducer (such as
indoleacrylic acid) if necessary, the desired thymosin β 15 may be
expressed. The extent of expression may be analyzed by SDS
20 polyacrylamide gel electrophoresis-SDS-PAGE (Lemelli, *Nature*
227:680-685 (1970)).

Suitable methods for growing and transforming cultures etc. are
usefully illustrated in, for example, Maniatis (*Molecular Cloning, A*
25 *Laboratory Notebook*, Maniatis et al. (eds.), Cold Spring Harbor Labs,
N.Y. (1989)).

Cultures useful for production of thymosin β 15, or a peptide
thereof, may suitably be cultures of any living cells, and may vary from

- 14 -

prokaryotic expression systems up to eukaryotic expression systems. One preferred prokaryotic system is that of *E. coli*, owing to its ease of manipulation. However, it is also possible to use a higher system, such as a mammalian cell line, for expression of a eukaryotic protein.

5 Currently preferred cell lines for transient expression are the HeLa and Cos cell lines. Other expression systems include the Chinese Hamster Ovary (CHO) cell line and the baculovirus system.

Other expression systems which may be employed include
10 streptomycetes, for example, and yeasts, such as *Saccharomyces* spp., especially *S. cerevisiae*. Any system may be used as desired, generally depending on what is required by the operator. Suitable systems may also be used to amplify the genetic material, but it is generally convenient to use *E. coli* for this purpose when only proliferation of the
15 DNA is required.

Standard detection techniques well known in the art for detecting RNA, DNA, proteins and peptides can readily be applied to detect thymosin β 15 or its transcript to diagnose cancer, especially
20 metastatic cancer or to confirm that a primary tumor has, or has not, reached a particular metastatic phase.

In one such technique, immunohistochemistry, anti-thymosin β 15 antibodies may be used to detect thymosin β 15 in a biopsy sample.
25

Anti-thymosin β 15 antibodies may also be used for imaging purposes, for example, to detect tumor metastasis. Suitable labels include radioisotopes, iodine (^{125}I , ^{121}I), carbon (^{14}C), sulphur (^{35}S), tritium (^3H), indium (^{112}In), and technetium ($^{99\text{m}}\text{Tc}$), fluorescent labels,

- 15 -

such as fluorescein and rhodamine, and biotin.

However, for *in vivo* imaging purposes, the position becomes more restrictive, as antibodies are not detectable, as such, from outside
5 the body, and so must be labelled, or otherwise modified, to permit detection. Markers for this purpose may be any that do not substantially interfere with the antibody binding, but which allow external detection. Suitable markers may include those that may be detected by X-radiography, NMR or MIR. For X-radiographic techniques,
10 suitable markers include any radioisotope that emits detectable radiation but that is not overtly harmful to the patient, such as barium or caesium, for example. Suitable markers for NMR and MIR generally include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by suitable labelling of
15 nutrients for the relevant hybridoma, for example.

In the case of *in vivo* imaging methods, an antibody or antibody fragment which has been labelled with an appropriate detectable imaging moiety, such as a radioisotope (for example, ^{131}I , ^{112}In , $^{99\text{m}}\text{Tc}$),
20 a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously or intraperitoneally) into the subject (such as a human) to be examined. The size of the subject, and the imaging system used, will determine the quantity of imaging moiety needed to produce diagnostic images. In
25 the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of technetium-99m. The labelled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain thymosin $\beta 15$. The labelled antibody or antibody fragment can then be

- 16 -

detected using known techniques.

The antibodies may be raised against either a peptide of thymosin β 15 or the whole molecule. Such a peptide may be presented together with a carrier protein, such as an KLH, to an animal system or, if it is long enough, say 25 amino acid residues, without a carrier. Preferred peptides include regions unique to thymosin β 15, such as amino acid 7 to 12 of SEQ ID NO: 2, amino acid 21 to 24 of SEQ ID NO: 2 and amino acid 36 to 45 of SEQ ID NO: 2.

10

Polyclonal antibodies generated by the above technique may be used direct, or suitable antibody producing cells may be isolated from the animal and used to form a hybridoma by known means (Kohler and Milstein, *Nature* 256:795. (1975)). Selection of an appropriate hybridoma will also be apparent to those skilled in the art, and the resulting antibody may be used in a suitable assay to identify thymosin β 15.

15

Antibodies, or their equivalents, may also be used in accordance with the present invention for the treatment or prophylaxis of cancers. Administration of a suitable dose of the antibody may serve to block production, or to block the effective activity of thymosin β 15, and this may provide a crucial time window in which to treat the malignant growth.

25

Prophylaxis may be appropriate even at very early stages of the disease, as it is not known what actually leads to metastasis in any given case. Thus, administration of the antibodies, their equivalents, or factors which interfere with thymosin β 15 activity, may be effected as

- 17 -

soon as cancer is diagnosed, and treatment continued for as long as is necessary, preferably until the threat of the disease has been removed.

Such treatment may also be used prophylactically in individuals at high risk for development of certain cancers, e.g., prostate.

5

A method of treatment involves attachment of a suitable toxin to the antibodies which then target the area of the tumor. Such toxins are well known in the art, and may comprise toxic radioisotopes, heavy metals, enzymes and complement activators, as well as such natural
10 toxins as ricin which are capable of acting at the level of only one or two molecules per cell. It may also be possible to use such a technique to deliver localized doses of suitable physiologically active compounds, which may be used, for example, to treat cancers.

15 It will be appreciated that antibodies for use in accordance with the present invention, whether for diagnostic or therapeutic applications, may be monoclonal or polyclonal as appropriate. Antibody equivalents of these may comprise: the Fab' fragments of the antibodies, such as Fab, Fab', F(ab')₂ and Fv; idiotopes; or the results of allotope grafting
20 (where the recognition region of an animal antibody is grafted into the appropriate region of a human antibody to avoid an immune response in the patient), for example. Single chain antibodies may also be used. Other suitable modifications and/or agents will be apparent to those skilled in the art.

25

Chimeric and humanized antibodies are also within the scope of the invention. It is expected that chimeric and humanized antibodies would be less immunogenic in a human subject than the corresponding non-chimeric antibody. A variety of approaches for making chimeric

- 18 -

antibodies, comprising for example a non-human variable region and a human constant region, have been described. See, for example, Morrison et al., Proc. Natl. Acad. Sci. U.S.A. 81,6851 (1985); Takeda et al., Nature 314,452(1985), Cabilly et al., U.S. Pat. No. 4,816,567; 5 Boss et al., U.S. Pat. No. 4,816,397; Tanaguchi et al., European Patent Publication EP 171496; European Patent Publication 0173494, United Kingdom Patent GB 2177096B. Additionally, a chimeric antibody can be further "humanized" such that parts of the variable regions, especially the conserved framework regions of the antigen-binding domain, are of 10 human origin and only the hypervariable regions are of non-human origin. Such altered immunoglobulin molecules may be made by any of several techniques known in the art, (e.g., Teng et al., Proc. Natl. Acad. Sci. U.S.A., 80, 7308-7312 (1983); Kozbor et al., Immunology Today, 4, 7279 (1983); Olsson et al., Meth. Enzymol., 15 92, 3-16 (1982)), and are preferably made according to the teachings of PCT Publication WO92/06193 or EP 0239400. Humanized antibodies can be commercially produced by, for example, Scotgen Limited, 2 Holly Road, Twickenham, Middlesex, Great Britain.

20 Another method of generating specific antibodies, or antibody fragments, reactive against thymosin β 15 is to screen phage expression libraries encoding immunoglobulin genes, or portions thereof, with a protein of the invention, or peptide fragment thereof. For example, complete Fab fragments, V H regions and V-region derivatives can be 25 expressed in bacteria using phage expression libraries. See for example Ward, et al., *Nature* 341,544-546: (1989); Huse, et al., *Science* 246, 1275-1281 (1989); and McCafferty, et al., *Nature* 348, 552-554 (1990).

- 19 -

The antibody can be administered by a number of methods. One preferred method is set forth by Marasco and Haseltine in PCT WO94/02610, which is incorporated herein by reference. This method discloses the intracellular delivery of a gene encoding the antibody, in this case the thymosin β 15 antibody. One would preferably use a gene encoding a single chain thymosin β 15 antibody. The antibody would preferably contain a nuclear localization sequence, for example Pro-Lys-Lys-Lys-Arg-Lys-Val (SEQ ID NO:4) [Lawford, et al. *Cell* 46:575 (1986)]; Pro-Glu-Lys-Lys-Ile-Lys-Ser (SEQ ID NO:5) [Stanton, et al., *Proc. Natl. Acad. Sci. USA* 83:1772 (1986)], Gln-Pro-Lys-Lys-Pro (SEQ ID NO:6) [Harlow, et al., *Mol. Cell. Biol.* 5:1605 (1985)]; Arg-Lys-Lys-Arg (SEQ ID NO:7) for the nucleus. One preferably uses an SV40 nuclear localization signal. By this method one can intracellularly express a thymosin β 15 antibody, which can block thymosin β 15 functioning in desired cells.

In addition to using antibodies to inhibit thymosin β 15, it may also be possible to use other forms of inhibitors. Inhibitors of thymosin β 15 may be manufactured, and these will generally correspond to the area of the substrate affected by the enzymatic activity. It is generally preferred that such inhibitors correspond to a frozen intermediate between the substrate and the cleavage products, but it is also possible to provide a sterically hindered version of the binding site, or a version of the binding site which will, itself, irreversibly bind to thymosin β 15. Other suitable inhibitors will be apparent to the skilled person.

The invention also provides for the treatment of a cancer by altering the expression of the thymosin β 15. This may be effected by

- 20 -

interfering with thymosin β 15 production, such as by directing specific antibodies against the protein, which antibodies may be further modified to achieve the desired result. It may also be possible to block the thymosin β 15 receptor, something which may be more easily
5 achieved by localization of the necessary binding agent, which may be an antibody or synthetic peptide, for example.

Affecting thymosin β 15 gene expression may also be achieved more directly, such as by blocking of a site, such as the promoter, on
10 the genomic DNA.

Where the present invention provides for the administration of, for example, antibodies to a patient, then this may be by any suitable route. If the tumor is still thought to be, or diagnosed as, localized,
15 then an appropriate method of administration may be by injection direct to the site. Administration may also be by injection, including subcutaneous, intramuscular, intravenous and intradermal injections.

Formulations may be any that are appropriate to the route of
20 administration, and will be apparent to those skilled in the art. The formulations may contain a suitable carrier, such as saline, and may also comprise bulking agents, other medicinal preparations, adjuvants and any other suitable pharmaceutical ingredients. Catheters are another preferred mode of administration.

25

Thymosin β 15 expression may also be inhibited *in vivo* by the use of antisense technology. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a

- 21 -

polynucleotide to DNA or RNA. An antisense nucleic acid molecule which is complementary to a nucleic acid molecule encoding thymosin β 15 can be designed based upon the isolated nucleic acid molecules encoding thymosin β 15 provided by the invention. An antisense nucleic acid molecule can comprise a nucleotide sequence which is complementary to a coding strand of a nucleic acid, e.g. complementary to an mRNA sequence, constructed according to the rules of Watson and Crick base pairing, and can hydrogen bond to the coding strand of the nucleic acid. The antisense sequence complementary to a sequence of an mRNA can be complementary to a sequence in the coding region of the mRNA or can be complementary to a 5' or 3' untranslated region of the mRNA. Furthermore, an antisense nucleic acid can be complementary in sequence to a regulatory region of the gene encoding the mRNA, for instance a transcription initiation sequence or regulatory element. Preferably, an antisense nucleic acid complementary to a region preceding or spanning the initiation codon or in the 3' untranslated region of an mRNA is used. An antisense nucleic acid can be designed based upon the nucleotide sequence shown in SEQ ID NO: 1. A nucleic acid is designed which has a sequence complementary to a sequence of the coding or untranslated region of the shown nucleic acid. Alternatively, an antisense nucleic acid can be designed based upon sequences of a β 15 gene, which can be identified by screening a genomic DNA library with an isolated nucleic acid of the invention. For example, the sequence of an important regulatory element can be determined by standard techniques and a sequence which is antisense to the regulatory element can be designed.

The antisense nucleic acids and oligonucleotides of the invention

- 22 -

can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. The antisense nucleic acid or oligonucleotide can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids e.g. phosphorothioate derivatives and acridine substituted nucleotides can be used. Alternatively, the antisense nucleic acids and oligonucleotides can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e. nucleic acid transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest). The antisense expression vector is introduced into cells in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. et al., Antisense RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics, Vol. 1 (1)1986.

In addition, ribozymes can be used to inhibit *in vitro* expression of thymosin β 15. For example, the nucleic acids of the invention can further be used to design ribozymes which are capable of cleaving a single-stranded nucleic acid encoding a β 15 protein, such as a thymosin β 15 mRNA transcript. A catalytic RNA (ribozyme) having ribonuclease activity can be designed which has specificity for an mRNA encoding thymosin β 15 based upon the sequence of a nucleic acid of the invention (e.g., SEQ ID NO: 1). For example, a derivative of a

- 23 -

Tetrahymena L-19 IVS RNA can be constructed in which the base sequence of the active site is complementary to the base sequence to be cleaved in a thymosin β 15-encoding mRNA. See for example Cech, et al., U.S. Pat. No. 4,987,071; Cech, et al., U.S. Pat. No. 5,116,742.

5 Alternatively, a nucleic acid of the invention could be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See for example Bartel, D. and Szostak, J. W. *Science* 261,1411-1418 (1993).

10 Methods for the diagnosis and prognosis of cancer using the polynucleotides and antibodies of the present invention are set forth in copending application U.S.S.N. 08/664,857, the disclosure of which is herein incorporated by reference.

15 All references cited above or below are herein incorporated by reference.

The following Examples serve to illustrate the present invention, and are not intended to limit the invention in any manner.

20

EXAMPLES

METHODS

Cell Culture

25 The poorly metastatic AT2.1 subline and high metastatic AT3.1, AT6.1 and Mat lylu sublines derived from Dunning R3327 rat prostatic adenocarcinoma cells (provided by Dr. J. Issaacs, The Johns Hopkins University) were maintained in vitro in RPMI 1640 medium, supplemented with 10% fetal bovine serum (Hyclone Laboratories, Logan, UT), 1% glutamine/penicillin/streptomycin (Irvine Scientific,

- 24 -

Logan, UT), 1 % glutamine/penicillin/streptomycin (Irvine Scientific, Santa Ana, CA), and 250 nM dexamethasone (Sigma Chemical Co, St. Louis, MD), under an atmosphere of 5% CO₂; 95% air at 37°C.

5 RNA Isolation and Northern Blot Analysis

Cells at 70% confluency were harvested and subjected to RNA isolation. Total RNA was prepared by acid guanidinium thiocyanate/phenol/chloroform extraction procedures. (Chomczynski, P. & Sacchi, *Anal. Biochem.* **167**, 157-159 (1987)). Poly (A) RNAs
10 were isolated from total RNA using Poly (A) Quik mRNA Isolation Kit (Stratagene, La Jolla, CA) or Micro Fast Track mRNA Isolation Kit (Invitrogen, San Diego, CA). 20 µg of total RNA or 2 µg of mRNA was size fractionated on a denaturing formaldehyde agarose gel (1.1 %) and transferred onto Hybond-N⁺ membrane (Amersham Corporation,
15 Arlington Heights, IL) by capillary blotting in 0.05 M NaOH buffer according to the manufacturer's procedure. Northern blot filters were prehybridized for 3 hours at 42°C in 5x Denhardt's, 50% formamide, 5x SSPE, 0.5% SDS solution containing 100 µg/ml denatured salmon sperm DNA (Stratagene), followed by overnight hybridization in fresh
20 prehybridization solution with the addition of denatured probe labeled with [alpha-³²P] dCTP (New England Nuclear, Wilmington, DE) using random primed DNA labeling kit (Boehringer Mannheim Biochemica, Indianapolis, IN). Filters were washed at increasing stringency to a final stringency of 0.2 x SSC; 0.1% SDS at 55°C. Autoradiography
25 was performed over two days at -80°C using Kodak X-Omat's film with intensifying screen. For reprobing, the original probe was removed by the blots with boiling in 0.5% SDS water for 10 min.

mRNA differential display

- 25 -

DNase I digested 2 µg of total RNA from AT2.1, AT3.1 and AT6.1 cells grown to 70% confluency in RPMI 1640 medium supplemented with 10% fetal bovine serum and 250 nM dexamethasone were reverse-transcribed with 300 units of MMLV reverse transcriptase (Stratagene) in the presence of 2.5 µM of T 11 AG as primer and 20 µM dNTP for 60 min at 35°C. After heat inactivation of the reverse transcriptase at 95°C for 5 min, 2 µl of the sample was amplified by PCR with T11 AG primer and arbitrary 10 mers in the presence of [α -³⁵S]dATP (New England Nuclear). The PCR parameters were 94°C for 30 sec, 42°C for 1 min, and 72°C for 30 sec for 40 cycles, followed by 5 min elongation at 72°C. PCR products were fractionated on a 6% polyacrylamide gel and visualized by autoradiography. Differentially expressed bands were cut out of the dried gels and reamplified by PCR using the corresponding sets of primers. The reamplified PCR fragments were used as probes for Northern blot analysis.

cDNA library screening

An oligo(dT)-primed cDNA library was constructed in the lambda gt10 vector (Amersham) using polyadenylated [poly(A)⁺] RNA obtained from AT3.1 cells in culture. The library was screened with a ³²P-labeled probe generated by PCR, using a 343 base pair AT3.1 cDNA isolated from differential display as template. Filters were hybridized with probe overnight at 65°C in a 5x Denhardt's, 5x SSPE, 0.5% SDS solution containing 100 µg/ml denatured salmon sperm DNA, and washed at high stringency with 0.2 x saline sodium citrate (SSC) and 0.1% SDS at 65°C. Inserts of positive clones were excised from lambda gt10 vector with EcoRI enzyme, subcloned into pbluescript II SK +/- (Stratagene) and sequenced using the Sequenase Version 2.0

- 26 -

sequencing kit (U.S. Biochemical, Cleveland, OH).

RT-PCR Analysis

Total RNA from each cell line was digested with RNase free
5 DNase I (GIBCO BRL, Gaithersburg, MD). DNase I digested 5 µg of total
RNA was reverse transcribed using cDNA Cyling Kit (Invitrogen). The
reverse transcription mixture was purified with a Spin Column 300
(Pharmocia, Piscataway, NJ). 10 µl of purified cDNA was amplified
with primer sets of Tβ15 forward primer:
10 5'-TATCAGCTAGTGGCTGCACCCGCG-3' (SEQ ID NO:8) and reverse
primer: 5'-AAATGCTGACCTTTCAGTCAGGGT-3' (SEQ ID NO:9); Tβ4
forward primer: 5'-ACTCTCAATTCCACCA TCTCCCAC-3' (SEQ ID
NO:10), reverse primer: 5'-GCCTCTGAGCAGATCGTCTCTCCTTG-3'
(SEQ ID NO:11); and Tβ10 forward primer:
15 5'-ATAATATCCCTGGGCAAACCGGTG-3' (SEQ ID NO:12), reverse
primer: 5'-GAGTGGAG TACCTGGAGCGCGAGC-3' (SEQ ID NO:13),
respectively. PCR amplification was performed in 50 µl of PCR reaction
buffer (50 mM KCl, 10 mM Tris [pH 8.5], 1.5 mM MgCl₂) with 1 mM
of dNTPs, 50 pmol of each primer, and 2.5 U of Taq polymerase
20 (GIBCO BRL), overlaid with 50 µl of mineral oil (Sigma). The PCR profile
was 94°C, 30 sec; 60°C, 30 sec; and 72°C, 2 min for 30 cycles.
Control studies of the RT-PCR were conducted using aliquats from the
same samples and amplified with primers to the β-actin gene (Clontech,
Palo Alto, CA). Amplification products were separated on 1.4%
25 agarose gels.

In situ hybridization

Antisense and sense Tβ15 mRNA probes were prepared using
Tβ15 cDNA inserted into the eukaryotic expression vector pcDNA3
(Invitrogen) as template and a digoxigenin RNA labeling kit (Boehringer

- 27 -

Mannheim). Formalin-fixed paraffin-embedded sections were dewaxed, rehydrated, and digested with proteinase K (50 µg/ml) in 100 mM Tris, 50 mM EDTA buffer (pH 8) for 8 min at 37°C. Hybridization was performed in an automated instrument (Ventana Medical Systems, Tuscon, AZ) for 60 min at 42°C with 10 pM digoxigenin-labeled riboprobe in 100 µl of hybridization buffer (50% deionized formamide, 4x SSC, 10% dextran sulfate, 1% SDS, and denatured herring sperm DNA (400 µg/ml)) per section under a liquid cover slip. The highest stringency of posthybridization washes was at 45°C for 15 min in 0.1 x SSC. Bound digoxigenin-labeled probe was detected by anti-digoxigenin alkaline phosphatase conjugate and visualized by nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate (NBT-BCIP) color reaction. Sections were counterstained with nuclear fast red.

15

GST-Tβ fusion protein expression

PCR generated DNA fragments containing the full coding regions of Tβ15 and Tβ4 were ligated in frame into the BamHI-EcoRI site of the prokaryotic expression vector pGEX-2T (Pharmacia, Piscataway, NJ). The pGEX-Tβ fusions were expressed in *Escherichia coli*, strain DH5α, by incubating with 0.1 mM isopropylthio-β-D-galactoside for 3 hours. Cells were recovered by centrifugation, washed, and suspended in phosphate buffered saline (PBS) containing 0.15 µg/ml aprotinin and 1mM EDTA and lysed by sonication. After addition of Triton X-100 to a final concentration of 0.1% (v/v), intact cells and debris were removed by centrifugation. The supernatant was incubated with a 50% (v/v) slurry of glutathione-agarose (Pharmacia) in PBS. After the beads were washed with excess PBS and poured into a column, fusion proteins were eluted with a solution containing 50 mM Tris-HCl (pH

25

- 28 -

8.0) and 10 mM reduced glutathione (Sigma).

Actin binding experiment

Pyrene-labeled G-actin was prepared as previously described
5 (Kouyama, et al., *Eur. J. Biochem* 114, 33-38 (1981). The final extents
of polymerization were determined from the final levels of fluorescence
of pyrene-labeled actin as previously described (Janmey, et al.
Biochemistry 24, 3714-3723 (1985).

10 **Transfection**

T β 15 cDNA was cloned into pcDNA3 in either the sense or
antisense orientation relative to the constitutive human
cytomegalovirus promoter and transfected into cells using lipofectin
(GIBCO BRL, Gaithersburg, MD). Individual stable transfectants were
15 selected in media containing 600 μ g/ml of G418 (GIBCO BRL). Control
transfections were done with pcDNA3 DNA devoid of T β 15.

Cell motility

Migration of transfectants was studied using a multiwell chamber
20 assay as previously described (Kunda, et al., *J. Cell Biol.* 130, 725
(1995)) 48-well chemotaxis chambers were overlaid with 8- μ m
porosity polycarbonate filters (Nucleopore Corp., Pleasanton, CA)
precoated with PBS containing 11.5 μ g/ml fibronectin (Cappel Organon
Technica, Durham, NC). The migration of 5,000 cells placed in the
25 upper well toward fetal bovine serum in the lower well was assayed
following a 4 hour incubation at 37°C. After removal of cells from the
upper side of the filters, cells that had passed through the filters and
adhered to the lower side were fixed in formalin, washed with PBS and
stained with Gill's triple strength hematoxylin (Polysciences,

Warrington, PA) and counted under light microscopy.

Generation of polyclonal antibody

0.25 mg of a synthetic oligopeptide (IQQEKEYNQRS)
5 representing the 11 carboxyl terminal amino acids of thymosin β 15 dissolved in 380 ml of a 0.125 M phosphate buffer, pH 7.4 was pipetted into reaction vessel containing 1.0 mg of keyhole limpet hemocyanin (Sigma). Then, 20 μ l of 25% aqueous glutaraldehyde solution was added. After gentle agitation, first for 3 h at room
10 temperature and then for 12 h at 4°C, the reaction mixture was diluted with 0.15 M NaCl to a final concentration of 100 μ g/ml. The diluted mixture was then used for immunization. New Zealand White rabbits were immunized with 30 μ g of the C-terminal peptide of thymosin β 15 as KLH conjugate emulsified with CFA. The first booster injection was
15 given 6 weeks after the first immunization. Whereas subsequent booster injections were given at 3 weeks intervals. Production bleeds were obtained 2 weeks after the fifth boost. Antisera were affinity purified over the C-terminal peptide conjugated CNBr-activated Sepharose 4B column (Pharmacia) in 10 mM Tris-HCl, pH 7.4. After
20 extensive washing of the column with 0.5 M NaCl, 10 mM Tris, pH 7.4, the column was eluted with 0.2 M Glycine, 0.2 NaCl, pH 2.0. The purity and specificity of eluted fractions were examined by Western analysis.

25 **Western analysis**

GST-T β fusion proteins were run on a 12% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane (0.2mm, Schleicher & Schuell, Keene, NH). The blot was incubated with 5% nonfat dry milk in phosphate-buffered saline containing 0.1% Tween 20 (TBS-T)

- 30 -

followed by incubation with the 1: 1000 diluted affinity purified anti T β 15 C-terminal peptide antidody for 1 h and washed 3 times with TBS-T. The blot was then incubated with horseradish peroxidase-conjugated anti-rabbit IgG antibody (Amersham Corp.) for 40 min, and a specific antibody reaction was detected by an enhanced chemiluminescence detection system (Amersham Corp.).

Immunohistochemical staining

Human prostate cancer sections were studied using an immunoperoxidase ABC kit (Vector, Burlingame, CA). Briefly, the 5 μ m tissue sections were deparaffinized in xylene, rehydrated in graded alcohols, and blocked for endogenous peroxidase by 3% hydrogen peroxide (Sigma) in methanol for 30 min. The sections were treated with normal goat serum for 30 min and then incubated with an affinity purified anti T β 15 C-terminal peptide antibody for 2 h at room temperature at 1:100 (v/v) dilution, followed by incubation with a biotinylated goat anti-rabbit IgG antibody for 30 min. After incubation with a preformed ABC complex for 30 min, specifically bound antibodies were visualized by using peroxidase substrate, 3, 3'-diaminobenzidine tetrahydrochloride (DAB). Sections were counterstained with Gill's hematoxylin.

RESULTS

Cloning of T β 15

We compared patterns of gene expression by mRNA differential display analysis (Liang, P. & Pardee, A.B., *Science* **257**, 967-971 (1992) in three variants of the Dunning rat tumor: the weakly metastatic, poorly motile line AT2.1 and the highly metastatic, highly motile lines AT3.1 and AT6.1. One band, which was detected in the

- 31 -

more motile AT3.1 and AT6.1 lines by differential display (Figure 1A) was confirmed by Northern (RNA) analysis to represent an overexpressed mRNA of approximately 420 nucleotides in AT3.1, AT6.1 as well as the related MatLyLu cell line but was not expressed in the poorly motile AT2.1 line (Figure 1B). The gene was not expressed in other rat prostatic cell lines (non-metastatic) characterized by Northern analysis (data not shown).

To obtain a full-length complementary DNA (cDNA) clone of this gene, an AT3.1 cDNA library was screened using the originally cloned cDNA fragment from differential display as a probe. A positive clone with a 412 base pair insert was isolated, which contained a single open-reading frame encoding a 45 amino acid protein with a calculated molecular mass of 5304 (Figure 2). The insert size of the clone was approximately the same as the molecular size of the transcript seen in Northern analysis suggesting that the clone contained the full length gene sequence. A computer assisted homology search against the Genebank and EMBL DNA databases revealed that the novel gene shared 49% nucleotide sequence homology with rat thymosins β 4 and β 10. Alignment of the deduced amino acid sequence of the cloned gene with members of the thymosin β family (Mihelic, M. & Voelter, *Amino Acids* 6, 1-13 (1994) showed 68% homology with thymosin β 4, 62% with thymosin β 10 and 60% with β 9, β 11 and β 12 (Figure 3). The results suggest that we have cloned a novel β thymosin, now named thymosin β 15, from rat prostatic carcinoma cells.

Hydropathy analysis of the thymosin β 15 protein sequence revealed no apparent membrane-spanning or membrane-associated regions and no amino-terminal signal sequence. The protein is highly

- 32 -

hydrophilic with an estimated isoelectric point of 5.14 and contains regions common to all members of the thymosin β family. All β -thymosin family members previously studied, for example, have a putative actin binding region (LKKTET) 16 residues from the amino
5 terminus (Vancompernelle, et al., *EMBO J.* **11**, 4739-4746 (1992), Troys, et al., *EMBO J.* **15**, 201-210 (1996). Thymosin β 15 also has such a region, although the glutamic acid residue is replaced by an asparagine residue to form LKKTNT (Figure 3). The principal region of nonconformity between members of the thymosin β family occurs at
10 the carboxyl terminus and the thymosin β 15 sequence as well shows no significant homology in this region with other family members.

Members of the β -thymosin family may be independently expressed in different tissues (Lin, et al., *J. Biol. Chem.* **266**,
15 23347-23353 (1991), Voisin, et al. *J. Neurochem.* **64**, 109-120 (1995). Although thymosin β 15 is differentially expressed in the prostate carcinoma cell lines tested, all of these lines expressed equivalent levels of thymosins β 4 and β 10 by RT-PCR analysis (Figure 11). The tissue distribution of thymosin β 15 mRNA was examined in
20 the major organs of the rat. No expression of thymosin β 15 was detected in the heart, brain, lung, spleen, liver, skeletal muscle and kidney, whereas high expression was found in the testis (Figure 4). Southern (DNA) analysis of Hind III-, EcoR I- and Pst I-restricted DNA from AT2.1 and AT3.1 cells with thymosin β 15 cDNA probe revealed
25 no gross structural alteration of the thymosin β 15 gene in the tumor cells (data not shown). These results demonstrate that a novel member of the thymosin β family is upregulated in metastatic rat prostatic carcinoma cell lines, whereas expression of other thymosin β family members (β 4 and β 10) remains unchanged.

Cloning of Human Thymosin β 15 by RT-PCR

DNase I digested 5 μ g of total RNA from human prostatic carcinoma cell line PC-3 was reverse transcribed using cDNA Cycling Kit (Invitrogen). The reverse transcription mixture was purified with a Spin Column 300 (Pharmacia, Piscataway, NY). 10 μ l of purified cDNA reaction was amplified with primers F1 (5'-TATCAGCTAGTGGCTGCACCCGCG-3') (SEQ ID NO:8) and R1 (5'-AAATGCT GACCTTTCAGTCAGGGT-3') (SEQ ID NO:9) designed to anneal to the outer ends of the thymosin β 15 sequence. PCR amplification was performed in 50 μ l of PCR reaction buffer (50 mM KCl, 10 mM Tris [pH 8.5], 1.5 mM MgCl₂) with 1 mM of dNTPs, 50 pmol of each primer, and 2.5 U of Taq polymerase (GIBCO BRL), overlaid with 50 μ l of mineral oil (Sigma). The PCR profile was 94°C, 30 sec; 60°C, 30 sec; and 72°C, 2 min for 30 cycles. Control studies of the RT-PCR were conducted using aliquats from the same samples and amplified with primers to the β -actin gene (Clontech, Palo Alto, CA). Amplification products were separated on 1.6% agarose gels. The amplified PCR product was ligated to pCR using TA cloning kit (Invitrogen, San Diego, (CA), and then DNA sequenced. The sequence of the PCR product of human prostatic carcinoma cells amplified by the thymosin β 15 primers was surprisingly 100% identical to the thymosin β 15 sequence obtained from the rat prostatic carcinoma cells.

25 Expression of T β 15 mRNA in human prostate cancer

To determine whether this thymosin family member may be expressed in human prostate cancer, we examined human prostatic carcinoma cell line PC-3 by RT-PCR with forward and reverse primers for thymosin β 15. The PC-3 cells showed a low level of thymosin β 15

- 34 -

expression. The DNA sequence of the amplified PCR product was 100% identical to the rat thymosin β 15 sequence. We conducted in situ hybridization study on samples from patients with varying grades of prostatic carcinomas using a thymosin β 15 probe. The tissue sections allowed direct comparison of normal and malignant elements on the same samples. The stromal elements within and around the tumor cell masses, as well as the nonmalignant prostatic epithelium adjacent to the tumor showed little background hybridization with the thymosin β 15 antisense probe. In contrast, specific tumor cell islands exhibited a strong specific thymosin β 15 signal when probed with antisense (Figure 5A, small arrow) but not with a sense RNA probe (data not shown). Although nearly all of the tumor cells in the positive islands expressed thymosin β 15 mRNA, not all patient specimens were positive and not all islands in a single prostate were positive (Figure 5A, large arrow). The majority of the negative tumor cells were in non-invasive in situ carcinomas whereas highly invasive tumors were consistently positive (Figure 5B). Thus a novel β thymosin, first detected in metastatic rat prostate carcinoma cell lines, is upregulated in human prostate cancer.

20

Effect of T β 15 on actin polymerization

Because thymosin β 15 retains a putative actin-binding domain, we tested its effect on actin polymerization using recombinant fusion proteins. The results, shown in Figure 6A, reveal that a glutathione-S-transferase (GST)/thymosin β 15 fusion protein inhibits polymerization of pyrene-derivatized actin monomers to an equal or slightly greater extent than a GST/thymosin b4 fusion protein, suggesting that these two proteins have similar actin-sequestering properties. Similar results were obtained when thymosin β 15 was

25

- 35 -

cleaved from the GST-fusion protein with thrombin and subsequently analyzed for its ability to inhibit the rate and extent of actin polymerization (Figure 6B and C). The difference in apparent affinity for actin between free and GST-fused thymosin β 15 is likely related to the GST-mediated dimerization of the fusion peptides to form complexes with two actin monomer binding sites that either bind actin more tightly or bind to the end of the growing filament, thereby inhibiting polymerization at low molar ratios to total actin. One example of such an effect is the strong retardation of actin assembly by actobindin, which appears to function as a dimer of thymosin-like actin binding sites (Bubb, et al., *Biochemistry* **34**, 3921-3926 (1995)).

Effect of T β 15 on cell motility

To determine whether thymosin β 15 expression had an effect on cell motility, we transfected highly motile AT3.1 cells with a eukaryotic expression vector (pcDNA3) containing the thymosin β 15 gene in antisense orientation driven by the constitutive human cytomegalovirus promoter. The transfected cells growing in selective (G418) media were examined for expression of antisense transcripts of the thymosin β 15 gene by strand-specific polymerase chain reaction (PCR) amplification (Zhou, et al., *Cancer Res.* **52**, 4280-4285 (1992)). Analysis of cell motility in a multiwell Boyden chamber apparatus (Boyden, S. V., *J. Exp. Med.* **115**, 453-466 (1962)) using fetal bovine serum as a migration stimulus revealed that the motility of the transfectants which showed expression of antisense transcripts was significantly reduced relative to the vector-only controls (Figure 7A). Two antisense transfected clones which did not express antisense transcripts failed to show any decreased rate of cell motility (data not shown). In a further experiment, poorly motile AT2.1 cells, transfected

- 36 -

with sense thymosin β 15 constructs and confirmed to express thymosin β 15 by Northern analysis, were shown to have significantly increased stimulated motility relative to their vector controls (Figure 7B). Both the sense and antisense thymosin β 15 transfectants showed similar rates of cell proliferation relative to controls suggesting differential specificity for different cellular events (Figure 7C). The results demonstrate that thymosin β 15, which is upregulated in the highly motile AT3.1 and AT6.1 Dunning tumor cell lines, is a positive regulator of cell motility which is an important component of cancer metastasis.

Immunohistochemical detection of T β 15 in prostate carcinoma

A polyclonal antibody was raised against a peptide representing the 11 C-terminal amino acids of thymosin β 15. Synthesized peptide was coupled with a carrier, keyhole limpet hemocyanin (KLH), and injected into rabbits. Antiserum was affinity-purified over the C-terminal peptide coupled CNBr-activated sepharose 4B column. To test the specificity of the purified antibody, we performed Western analysis of the GST/thymosin β fusion proteins with the affinity-purified anti C-terminal antibody. The purified antibody strongly reacted with GST-thymosin β 15 fusion protein, but did not cross react with GST-thymosin β 4, and not with GST alone (Figure 8) showing its specificity.

We used the affinity purified polyclonal thymosin β 15 antibody for immunohistochemical study of human prostate carcinoma. The results are summarized below in Table 1. The thymosin β 15 immunostaining was observed in the cytoplasm of epithelial cells in neoplastic prostates but not in normal prostates and not in the stromal

- 37 -

cells (Figure 10A, large arrow). Among the investigated malignant epithelia, the poorly differentiated prostate carcinomas displayed the most extensive and intense thymosin β 15 immunoreaction (Figure 10C), followed by moderately differentiated prostate carcinomas in which not all carcinomas expressed thymosin β 15 showing partial positivity (Figure 10B). In some cases, high-grade prostatic intraepithelial neoplasia (PIN) showed thymosin β 15 immunostaining, but to a lesser extent (Figure 10A, small arrow). In poorly differentiated invasive carcinoma, single cells invading stroma displayed intense staining (Figure 10D). The expression of thymosin β 15 well correlated with Gleason grade of prostate carcinoma.

TABLE 1

THYMOSIN β 15 EXPRESSION IN HUMAN PROSTATE CARCINOMA

Prostate	No.	Negative ^a	Partial ^b	Positive ^c
BPH	2	2	0	0
Ca Gleason 2 ~ 5	5	3	2	0
Ca Gleason 6 ~ 8	25	4	7	14
Ca Gleason 9 ~ 10	6	0	1	5
Ca (with met)	3	0	1	2

15

(BPH - Benign Prostate Hyperplasia; Ca - Carcinoma)

- a. less than 10% cells showing positivity
 b. heterogeneous staining with 30 ~ 75% of cells showing positivity
 c. homogeneous staining with 75 ~ 100% of cells showing positivity

20

- 38 -

Expression of thymosin β 15 mRNA in mouse lung carcinoma

To determine whether thymosin β 15 may be expressed in other kind of cancer cells, we tested mouse lung carcinoma cell lines by Northern analysis. The results showed the thymosin β 15 expression in
5 metastatic cell lines M27 and H59, but showed no expression in a nonmetastatic cell line LA-4 (Figure 9).

DISCUSSION

10 Progression to the metastatic stage is directly correlated with mortality from prostatic carcinoma. It therefore follows that the early diagnosis, prevention, or therapeutic treatment of metastatic progression would lead to more effective control of this disease. The Dunning R-3327 rat prostatic adenocarcinoma model provides several
15 sublines with varying metastatic ability, all of which derive from an original spontaneous tumor and which provide an opportunity to study the steps leading to prostate cancer metastases (Mohler, *Cancer Metast. Rev.* 12, 53-67 1993) and Pienta, et al. *Cancer Surveys* 11, 255-263 (1993)). By comparing gene expression among the Dunning
20 cells, we cloned a novel member of the thymosin β family, thymosin β 15, which is expressed in highly metastatic prostate cancer cells but not in non- or weakly metastatic cells. The related family members thymosin β 4 and β 10 are expressed equally in all of the cell lines tested such that their expression does not vary with increasing metastatic
25 potential.

Thymosin β 15 binds G-actin and retards actin polymerization. Because the highly motile prostate cancer cell lines showed high level expression of thymosin β 15, we tested whether thymosin β 15

- 39 -

transfection into the Dunning rat carcinoma cell lines could influence cell motility. Our results show clearly that transfection of sense or antisense thymosin β 15 constructs into rat prostatic carcinoma cells can significantly modulate stimulated cell migration, a property not
5 previously associated with β -thymosins. In cancer, the enhanced movement of malignant tumor cells through connective tissues is a major contributor to progression toward the metastatic stage. In order to metastasize, a tumor cell must initially dissociate from the primary tumor, migrate through connective tissue and capillary walls into the
10 circulatory system, and migrate again across the vascular wall into a secondary site. Therefore, increases in thymosin β 15 expression in malignant prostate carcinoma cells are believed to mediate an important change in tumor progression toward metastasis and that the expression of thymosin β 15 is a useful marker for diagnosis and prognosis of
15 cancer malignancy.

Cell motility is typically associated with coordinated disassembly and reformation of the cortical actin network (Cunningham, et al., *Science* 251, 1233-1236 (1991), Haugwitz, et
20 al., *Cell* 79, 303-314 (1994) and Stossel, *Science* 260, 1086-1094 (1993)) . Enhanced expression or activation of thymosin's actin binding function may therefore stimulate motility by enhancing the depolymerization phase of this process. The finding that a molecule which acts to retard actin polymerization may stimulate cell motility is
25 consistent with the recent finding of Hug et al. (Hug, et al., *Cell* 81, 591-600 (1995) which showed that over expression of an action capping protein in Dictyostelium cells led to an increased rate of cell motility. The findings on the relationship between actin depolymerization and increased motility also support our hypothesis

that the upregulation of thymosin β 15 may represent an important step in the progression of prostatic carcinoma to the metastatic state.

5 The finding that thymosin β 15, which is upregulated in more highly metastatic rat prostate cancer cell lines, is also upregulated in human prostate cancer is intriguing. At present, the best markers for prostate cancer, such as PSA expression, are most useful for early detection of prostate cancer. However, they do not allow any distinction of metastatic tumor from non-metastatic tumors.

10 This invention has been described in detail including the preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements thereon without departing from the spirit and scope of the invention as set forth in the claims.

- 41 -

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: BRUCE R. ZETTER AND LERE BAO
- (ii) TITLE OF THE INVENTION: HUMAN THYMOSIN β 15 GENE, PROTEIN AND USES THEREOF
- (iii) NUMBER OF SEQUENCES: 13
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN
 - (B) STREET: 130 WATER STREET
 - (C) CITY: BOSTON
 - (D) STATE: MA
 - (E) COUNTRY: USA
 - (F) ZIP: 02019
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ Version 1.5
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE: 17 JUN 1996
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: DAVID, RESNICK S
 - (B) REGISTRATION NUMBER: 34,235
 - (C) REFERENCE/DOCKET NUMBER: 46507
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 617-523-3400
 - (B) TELEFAX: 617-523-6440
 - (C) TELEX: 200291 STRE

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 412 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:
- (ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION: 98...232
- (D) OTHER INFORMATION: Exon 1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

TATCAGCTAG TGGCTGCACC CGCGAACACC ACCCTGGTCC GGAGTAGCTG CGGACAGAAT    60
TGCTGGCCTA GTAGAAGCTT TGGAACGAGC AGTCAAG ATG AGT GAT AAA CCA GAC    115
                               Met Ser Asp Lys Pro Asp
                               1                               5
TTA TCA GAA GTT GAA ACA TTT GAC AAA TCA AAG TTG AAG AAG ACT AAT    163
Leu Ser Glu Val Glu Thr Phe Asp Lys Ser Lys Leu Lys Lys Thr Asn
                               10                               15                               20
ACT GAA GAA AAG AAT ACT CTT CCT TCG AAG GAA ACT ATC CAG CAG GAG    211
Thr Glu Glu Lys Asn Thr Leu Pro Ser Lys Glu Thr Ile Gln Gln Glu
                               25                               30                               35
AAA GAA TAT AAT CAA AGA TC ATAAAATGAG ATTCTCCTCT CAAGAGCAAC TTCAAC    267
Lys Glu Tyr Asn Gln Arg Ser
                               40                               45
TTTGCTGGAT AGTCTTGGAT TTAGACATGT TTCTGTAAAC CTATCCAATA TGTAGACATT    327
TTAGGCGGTT CCTGATAGGT TCTTAAGTAC CCTGACTGAA AGGTCAGCAT TTAACACCAA    387
TCATTAATG TGTTTTCCAC TGCTC                                         412
    
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 45 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Ser Asp Lys Pro Asp Leu Ser Glu Val Glu Thr Phe Asp Lys Ser
 1                               5                               10                               15
Lys Leu Lys Lys Thr Asn Thr Glu Glu Lys Asn Thr Leu Pro Ser Lys
 20                               25                               30
Glu Thr Ile Gln Gln Glu Lys Glu Tyr Asn Gln Arg Ser
 35                               40                               45
    
```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Gln Pro Lys Lys Pro
1 5

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: N-terminal
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Arg Lys Lys Arg
1

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TATCAGCTAG TGGCTGCACC CGCG

24

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AAATGCTGAC CTTTCAGTCA GGGT

24

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

ACTCTCAATT CCACCATCTC CCAC

24

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GCCTCTGAGC AGATCGTCTC TCCTTG

26

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

ATAATATCCC TGGGCAAACC GGTG

24

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:

- 46 -

(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GAGTGGAGTA CCTGGAGCGC GAGC

24

- 47 -

What is claimed is:

1. An isolated antibody or antibody fragment which selectively binds human thymosin β 15.
2. The antibody fragment of claim 1, wherein said fragment is a Fab, Fab', F(ab')₂ or Fv fragment.
3. The antibody of claim 1, wherein said antibody is a single chain antibody.
4. The antibody of claim 1, wherein said antibody is humanized.
5. The antibody or antibody fragment of claim 1, wherein said antibody or antibody fragment is detectably labelled.
6. An isolated and purified human thymosin β 15 having the amino acid sequence set forth in SEQ ID NO.: 2.
7. An isolated and purified polypeptide comprising a peptide selected from the group consisting of amino acid 7 to 12 of SEQ ID NO: 2, amino acid 21 to 24 of SEQ ID NO: 2 and amino acid 36 to 45 of SEQ ID NO: 2.
8. An isolated polynucleotide encoding human thymosin β 15 comprising the amino acid sequence as set forth in SEQ ID NO:2.
9. An isolated polynucleotide encoding a polypeptide comprising

- 48 -

a peptide selected from the group consisting of amino acid 7 to 12 of SEQ ID NO: 2, amino acid 21 to 24 of SEQ ID NO: 2 and amino acid 39 to 44 of SEQ ID NO: 2.

10. The polynucleotide of claims 8 or 9 wherein the polynucleotide is DNA.

11. The polynucleotide of claims 8 or 9 wherein the polynucleotide is cDNA.

12. The polynucleotide of claims 8 or 9 wherein the polynucleotide is RNA.

13. An isolated polynucleotide having the nucleotide sequence of SEQ ID NO:1, or the complement thereto.

14. An isolated polynucleotide encoding human thymosin β 15 having the nucleotide sequence of nucleotides 98-232 of SEQ ID NO:1, or the complement thereto.

15. A recombinant vector containing the DNA of claim 13 or 14.

16. A host cell containing the vector of claim 15.

17. A method of treating a neoplastic cell expressing human thymosin β 15 comprising, administering to the cell an effective amount of a compound which suppresses the activity or production of the human thymosin β 15.

18. The method of claim 17, wherein the compound interferes with the expression of the human thymosin β 15 gene.

19. The method of claim 18, wherein expression of the gene is inhibited by administering antisense oligonucleotides.

20. The method of claim 17, wherein the compound is an antibody or fragment thereof or a single chain antibody.

21. An isolated nucleotide segment comprising at least 10 nucleotides and hybridizes under stringent conditions to a DNA fragment having the nucleotide sequence set forth in SEQ ID NO:1.

1/7



FIG. 1A

28S-

18S-

Tβ15

β-actin




FIG. 1B




FIG. 4

TATCAGCTAG TGGCTGCACC CGCGAACACC ACCCTGGTCC GGAGTAGCTG CGGACAGAAT 60

TGCTGGCCTA GTAGAAAGCCTT TGGAACGAGC AGTCAAG ATG AGT GAT AAA CCA GAC 115
M S D K P D

TTA TCA GAA GTT GAA ACA TTT GAC AAA TCA AAG TTG AAG AAG ACT AAT 163
L S E V E T F D K S K L K K T N

ACT GAA GAA AAG AAT ACT CTT CCT TCG AAG GAA ACT ATC CAG CAG GAG 211
T E E K N T L P S K E T I Q Q E

AAA GAA TAT AAT CAA AGA TC ATAAAAATGAG ATTCTCCTCT CAAGAGCAAC TTCAAC 267
K E T N Q R S *

TTTGCTGGAT AGTCTTGGAT TTAGACATGT TTCTGTAAAC CTATCCAATA TGTAGACATT 327
TTAGGCGGTT CCTGATAGGT TCTTAAAGTAC CCTGACTGAA AGGTCAGCAT TTAACACCAA 387
TCATTAAATG TGTTTCCAC TGCTC 412

FIG.2

Ratthymb4	.MSDKPDMAE	TEKFDKSKLE	KTETOEKNPL	PSKETIEQEK	QAGES	49
Bovthymb9	ACADKPDIGE	TNSFDKAKLE	KTETOEKNIL	PTKETIEQEK	QAK	50
Ratthymb10	.MADKPDME	IASFDKAKLE	KTETOEKNIL	PTKETIEQEE	RSETS	49
Troutthymb11	ACSDKPNLEE	VASFDKTKLE	KTETOEKNPI	PTKETIEQEE	QAS	50
Troutthymb12	ACSDKPDLAE	VSNFDKTKLE	KTETOEKNPL	PTKETIEQEE	QAT	50
Humanthymb15	.MSDKPDLUSE	VETFDKSKLE	KTNJEKNIL	PSKETIQEK	EYNQRS	49

FIG. 3




FIG. 5A




FIG. 5B

FIG.6A




FIG.6B





FIG.6C



5/7

FIG. 7A





FIG. 7B



6/7

FIG. 7C





FIG. 8A




FIG. 8B




FIG. 9




FIG. 11



FIG. 10B

FIG. 10A




FIG. 10D

FIG. 10C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/10315

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/16 C07K16/26 C12N15/85 C12N5/10 A61K31/70 C12N15/11 //C12Q1/68, C12N15/62				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07K				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	L. BAO ET AL.: "Differential expression of a novel mRNA in tumor cell lines with variant metastatic potential." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. ANNUAL MEETING, vol. 36, March 1995, BALTIMORE, MD, USA, page 85 XP002041934 cited in the application see abstract A505	6-16		
A	--- K. KWIATOWSKA ET AL.: "Beta-thymosin overexpression decreases the actin monomer pool and increases cell motility." MOLECULAR BIOLOGY OF THE CELL. SUPPLEMENT, vol. 6, 1995, BETHESDA, MD, USA, page 141A XP002041935 see abstract 816 --- -/--	6-16		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.				
<input checked="" type="checkbox"/> Patent family members are listed in annex.				
° Special categories of cited documents :				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none; vertical-align: top;"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family </td> </tr> </table>			*A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family			
Date of the actual completion of the international search <div style="text-align: center; font-size: 1.2em;">26 September 1997</div>	Date of mailing of the international search report <div style="text-align: center; font-size: 1.2em;">22. 10. 97</div>			
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <div style="text-align: center; font-size: 1.2em;">Nooij, F</div>			

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/10315

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	H-Q. SUN ET AL.: "Beta-thymosins are not simple actin monomer buffering proteins. Insights from overexpression studies." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 16, 19 April 1996, BALTIMORE, MD, USA, pages 9223-9230, XP002041936 see abstract ---	1-16
A	EP 0 121 912 A (F.HOFFMANN-LA ROCHE & CO.) 17 October 1984 see examples see claims ---	1-7
A	S. VARGHESE ET AL.: "Rat thymosin beta4 gene." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 22, 5 August 1991, BALTIMORE, MD, USA, pages 14256-14261, XP002041937 see the whole document ---	6-16
A	S. LIN ET AL.: "Cloning and characterization of a testis-specific thymosin beta10 cDNA." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 35, 15 December 1991, BALTIMORE, MD, USA, pages 23347-23353, XP002041938 see the whole document ---	1-16
P,X	L. BAO ET AL.: "Thymosin beta-15 is expressed in malignant human prostate carcinoma." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. ANNUAL MEETING, vol. 38, March 1997, BALTIMORE, MD, USA, pages 492-493, XP002041939 see abstract 3299 ---	1-16
P,X	B. ZETTER: "Thymosin beta 15." BIOMEDICINE AND PHARMACOTHERAPY, vol. 51, no. 4, 1997, PARIS, FRANCE, page 185 XP002041940 see upper-left abstract ---	6-16
P,X	L. BAO ET AL.: "Thymosin beta 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer." NATURE MEDICINE, vol. 2, no. 12, December 1996, NEW YORK, NY, USA, pages 1322-1328, XP002041941 see the whole document ---	1-21

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/10315

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	D. COFFEY: "Prostate cancer metastasis: talking the walk." NATURE MEDICINE, vol. 2, no. 12, December 1996, NEW YORK, NY, USA, pages 1305-1306, XP002041942 see the whole document -----	6-21

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/ 10315

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 17-20
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 17-20 (all partially, as far as an in vivo method is concerned) are directed to a method of treatment of the human/ animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/10315

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 121912 A	17-10-84	JP 60045598 A	12-03-85
